Adaptimmune <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces New Severance Compensation Plans for Key Executives Following Role Redundancies
Adaptimmune Therapeutics plc has announced new compensation agreements following the termination of several key executives due to redundancy. Dr. Elliot Norry, formerly the Chief Medical Officer, will receive a severance payment equivalent to 12 months of his 2025 base salary, totaling $478,135, along with a COBRA healthcare coverage payment of $30,965.73. Dr. Joanna Brewer, the outgoing Chief Scientific Officer, will receive £344,844 (approximately $460,639) as a severance payment, with an option for healthcare benefits reimbursement for a year. Gavin Wood, the former Chief Financial Officer, will be compensated with a 12-month base salary payment and a potential pro rata bonus of £111,417 (approximately $148,830), alongside healthcare benefits reimbursement for 12 months post-termination. All three executives have been granted a 12-month period to exercise their vested Market Value Options, in accordance with the company's 2016 Share Option Scheme.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adaptimmune Therapeutics plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001558370-25-010785), on August 07, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.